CAMBRIDGE, Mass. — A drug maker and medical research institute will work together to identify new treatments for bacterial and viral infections.
AstraZeneca and the Broad Institute, owned jointly by Harvard University and MIT, announced Monday that they would collaborate for two years to develop medicines to treat severe infections, saying the identification of high-quality chemicals for the development of new drugs was a significant challenge. The two will use the Broad Institute's collection of 100,000 chemicals known as diversity-oriented synthesis, or DOS compounds.
